Copyright Reports & Markets. All rights reserved.

Global Small Cell Lung Cancer Therapeutics Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Small Cell Lung Cancer Therapeutics Market Overview

    • 1.1 Product Overview and Scope of Small Cell Lung Cancer Therapeutics
    • 1.2 Classification of Small Cell Lung Cancer Therapeutics by Types
      • 1.2.1 Global Small Cell Lung Cancer Therapeutics Revenue Comparison by Types (2017-2023)
      • 1.2.2 Global Small Cell Lung Cancer Therapeutics Revenue Market Share by Types in 2017
      • 1.2.3 Biologics
      • 1.2.4 Small molecules
    • 1.3 Global Small Cell Lung Cancer Therapeutics Market by Application
      • 1.3.1 Global Small Cell Lung Cancer Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
      • 1.3.2 Hospitals
      • 1.3.3 Clinics
      • 1.3.4 Other
    • 1.4 Global Small Cell Lung Cancer Therapeutics Market by Regions
      • 1.4.1 Global Small Cell Lung Cancer Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
      • 1.4.1 North America (USA, Canada and Mexico) Small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)
    • 1.5 Global Market Size of Small Cell Lung Cancer Therapeutics (2013-2023)

    2 Manufacturers Profiles

    • 2.1 Sanofi
      • 2.1.1 Business Overview
      • 2.1.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Sanofi Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.2 Bristol-Myers Squibb
      • 2.2.1 Business Overview
      • 2.2.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Bristol-Myers Squibb Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.3 GlaxoSmithKline
      • 2.3.1 Business Overview
      • 2.3.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 GlaxoSmithKline Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.4 Menarini
      • 2.4.1 Business Overview
      • 2.4.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Menarini Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.5 Ziopharm Oncology
      • 2.5.1 Business Overview
      • 2.5.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Ziopharm Oncology Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.6 Merck
      • 2.6.1 Business Overview
      • 2.6.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Merck Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.7 Novartis
      • 2.7.1 Business Overview
      • 2.7.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Novartis Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.8 AstraZeneca
      • 2.8.1 Business Overview
      • 2.8.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 AstraZeneca Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.9 Takeda Pharmaceutical
      • 2.9.1 Business Overview
      • 2.9.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Takeda Pharmaceutical Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.10 Teva Pharmaceutical
      • 2.10.1 Business Overview
      • 2.10.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Teva Pharmaceutical Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.11 Eli Lilly
      • 2.11.1 Business Overview
      • 2.11.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Eli Lilly Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.12 Mylan
      • 2.12.1 Business Overview
      • 2.12.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.12.2.1 Product A
        • 2.12.2.2 Product B
      • 2.12.3 Mylan Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.13 Sun Pharmaceuticals Industries
      • 2.13.1 Business Overview
      • 2.13.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.13.2.1 Product A
        • 2.13.2.2 Product B
      • 2.13.3 Sun Pharmaceuticals Industries Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.14 Amgen
      • 2.14.1 Business Overview
      • 2.14.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.14.2.1 Product A
        • 2.14.2.2 Product B
      • 2.14.3 Amgen Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.15 Ono Pharmaceutical
      • 2.15.1 Business Overview
      • 2.15.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.15.2.1 Product A
        • 2.15.2.2 Product B
      • 2.15.3 Ono Pharmaceutical Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
    • 2.16 Shanghai Jinhe Bio-Technology
      • 2.16.1 Business Overview
      • 2.16.2 Small Cell Lung Cancer Therapeutics Type and Applications
        • 2.16.2.1 Product A
        • 2.16.2.2 Product B
      • 2.16.3 Shanghai Jinhe Bio-Technology Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

    3 Global Small Cell Lung Cancer Therapeutics Market Competition, by Players

    • 3.1 Global Small Cell Lung Cancer Therapeutics Revenue and Share by Players (2013-2018)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Small Cell Lung Cancer Therapeutics Players Market Share
      • 3.2.2 Top 10 Small Cell Lung Cancer Therapeutics Players Market Share
    • 3.3 Market Competition Trend

    4 Global Small Cell Lung Cancer Therapeutics Market Size by Regions

    • 4.1 Global Small Cell Lung Cancer Therapeutics Revenue and Market Share by Regions
    • 4.2 North America Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 4.3 Europe Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 4.4 Asia-Pacific Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 4.5 South America Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 4.6 Middle East and Africa Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

    5 North America Small Cell Lung Cancer Therapeutics Revenue by Countries

    • 5.1 North America Small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)
    • 5.2 USA Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 5.3 Canada Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 5.4 Mexico Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

    6 Europe Small Cell Lung Cancer Therapeutics Revenue by Countries

    • 6.1 Europe Small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)
    • 6.2 Germany Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 6.3 UK Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 6.4 France Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 6.5 Russia Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 6.6 Italy Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

    7 Asia-Pacific Small Cell Lung Cancer Therapeutics Revenue by Countries

    • 7.1 Asia-Pacific Small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)
    • 7.2 China Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 7.3 Japan Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 7.4 Korea Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 7.5 India Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 7.6 Southeast Asia Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

    8 South America Small Cell Lung Cancer Therapeutics Revenue by Countries

    • 8.1 South America Small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)
    • 8.2 Brazil Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 8.3 Argentina Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 8.4 Colombia Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

    9 Middle East and Africa Revenue Small Cell Lung Cancer Therapeutics by Countries

    • 9.1 Middle East and Africa Small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)
    • 9.2 Saudi Arabia Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 9.3 UAE Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 9.4 Egypt Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 9.5 Nigeria Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
    • 9.6 South Africa Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

    10 Global Small Cell Lung Cancer Therapeutics Market Segment by Type

    • 10.1 Global Small Cell Lung Cancer Therapeutics Revenue and Market Share by Type (2013-2018)
    • 10.2 Global Small Cell Lung Cancer Therapeutics Market Forecast by Type (2018-2023)
    • 10.3 Biologics Revenue Growth Rate (2013-2023)
    • 10.4 Small molecules Revenue Growth Rate (2013-2023)

    11 Global Small Cell Lung Cancer Therapeutics Market Segment by Application

    • 11.1 Global Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2013-2018)
    • 11.2 Small Cell Lung Cancer Therapeutics Market Forecast by Application (2018-2023)
    • 11.3 Hospitals Revenue Growth (2013-2018)
    • 11.4 Clinics Revenue Growth (2013-2018)
    • 11.5 Other Revenue Growth (2013-2018)

    12 Global Small Cell Lung Cancer Therapeutics Market Size Forecast (2018-2023)

    • 12.1 Global Small Cell Lung Cancer Therapeutics Market Size Forecast (2018-2023)
    • 12.2 Global Small Cell Lung Cancer Therapeutics Market Forecast by Regions (2018-2023)
    • 12.3 North America Small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)
    • 12.4 Europe Small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)
    • 12.5 Asia-Pacific Small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)
    • 12.6 South America Small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)
    • 12.7 Middle East and Africa Small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or radon. The common symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Small cell lung cancer has a poor prognosis and gets diagnosed only at the late stage of disease progression, and hence, has a high mortality rate. There are no therapies available to cure small cell lung cancer in the market.

      Scope of the Report:
      This report studies the Small Cell Lung Cancer Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Small Cell Lung Cancer Therapeutics market by product type and applications/end industries.
      The global Small Cell Lung Cancer Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Small Cell Lung Cancer Therapeutics.
      Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

      Market Segment by Companies, this report covers
      Sanofi
      Bristol-Myers Squibb
      GlaxoSmithKline
      Menarini
      Ziopharm Oncology
      Merck
      Novartis
      AstraZeneca
      Takeda Pharmaceutical
      Teva Pharmaceutical
      Eli Lilly
      Mylan
      Sun Pharmaceuticals Industries
      Amgen
      Ono Pharmaceutical
      Shanghai Jinhe Bio-Technology

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Biologics
      Small molecules

      Market Segment by Applications, can be divided into
      Hospitals
      Clinics
      Other

      Buy now